Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer

被引:147
作者
Dollins, Claudia M. [1 ]
Nair, Smita [1 ]
Boczkowski, David [1 ]
Lee, Jaewoo [1 ]
Layzer, Juliana M. [1 ]
Gilboa, Eli [2 ]
Sullenger, Bruce A. [1 ]
机构
[1] Duke Univ, Med Ctr, Duke Translat Res Inst, Dept Surg, Durham, NC 27710 USA
[2] Univ Miami, Dept Microbiol & Immunol, Sch Med, Miami, FL 33136 USA
来源
CHEMISTRY & BIOLOGY | 2008年 / 15卷 / 07期
关键词
D O I
10.1016/j.chembiol.2008.05.016
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We show that a molecular scaffold can be utilized to convert a receptor binding aptamer into a receptor agonist. Many receptors (including tumor necrosis receptor family members) are activated when they are multimerized on the cell surface. Molecular scaffolds have been utilized to assemble multiple receptor binding peptide ligands to generate activators of such receptors. We demonstrate that an RNA aptamer that recognizes OX40, a member of the tumor necrosis factor receptor superfamily, can be converted into a receptor-activating aptamer by assembling two copies on an olignucleotide-based scaffold. The OX40 receptor-activating aptamer is able to induce nuclear localization of nuclear factor-kappa B, cytokine production, and cell proliferation, as well as enhance the potency of dendritic cell-based tumor vaccines when systemically delivered to mice.
引用
收藏
页码:675 / 682
页数:8
相关论文
共 31 条
[1]   Signalling pathways of the TNF superfamily: A double-edged sword [J].
Aggarwal, BB .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (09) :745-756
[2]   Anti-tumour therapeutic efficacy of OX40L in murine tumour model [J].
Ali, SA ;
Ahmad, M ;
Lynam, J ;
McLean, CS ;
Entwisle, C ;
Loudon, P ;
Choolun, E ;
McArdle, SEB ;
Li, G ;
Mian, S ;
Rees, RC .
VACCINE, 2004, 22 (27-28) :3585-3594
[3]   OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand [J].
AlShamkhani, A ;
Birkeland, ML ;
Puklavec, M ;
Brown, MH ;
James, W ;
Barclay, AN .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (08) :1695-1699
[4]   Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with Neovascular age-related macular degeneration [J].
Apte, Rajendra S. .
OPHTHALMOLOGY, 2007, 114 (09) :1702-1712
[5]   4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor κB [J].
Arch, RH ;
Thompson, CB .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (01) :558-565
[6]   Direct in vitro selection of a 2′-O-methyl aptamer to VEGF [J].
Burmeister, PE ;
Lewis, SD ;
Silva, RF ;
Preiss, JR ;
Horwitz, LR ;
Pendergrast, PS ;
McCauley, TG ;
Kurz, JC ;
Epstein, DM ;
Wilson, C ;
Keefe, AD .
CHEMISTRY & BIOLOGY, 2005, 12 (01) :25-33
[7]   The crystal structure of the costimulatory OX40-OX40L complex [J].
Compaan, Deanne M. ;
Hymowitz, Sarah G. .
STRUCTURE, 2006, 14 (08) :1321-1330
[8]   First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology - A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity [J].
Dyke, Christopher K. ;
Steinhubl, Steven R. ;
Kleiman, Neal S. ;
Cannon, Richard O. ;
Aberle, Laura G. ;
Lin, Min ;
Myles, Shelley K. ;
Melloni, Chiara ;
Harrington, Robert A. ;
Alexander, John H. ;
Becker, Richard C. ;
Rusconi, Christopher P. .
CIRCULATION, 2006, 114 (23) :2490-2497
[9]   INVITRO SELECTION OF RNA MOLECULES THAT BIND SPECIFIC LIGANDS [J].
ELLINGTON, AD ;
SZOSTAK, JW .
NATURE, 1990, 346 (6287) :818-822
[10]  
Fitzwater T, 1996, METHOD ENZYMOL, V267, P275